Meeder Advisory Services Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Meeder Advisory Services Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,708 shares of the biopharmaceutical company’s stock after selling 247 shares during the period. Meeder Advisory Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,217,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of REGN. Quantbot Technologies LP purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $151,000. Paloma Partners Management Co increased its stake in shares of Regeneron Pharmaceuticals by 1,789.2% in the third quarter. Paloma Partners Management Co now owns 625 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 662 shares during the last quarter. Bamco Inc. NY acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $4,731,000. Benjamin Edwards Inc. raised its holdings in Regeneron Pharmaceuticals by 12,448.0% in the third quarter. Benjamin Edwards Inc. now owns 3,137 shares of the biopharmaceutical company’s stock valued at $3,298,000 after acquiring an additional 3,112 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Regeneron Pharmaceuticals by 76.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 23,591 shares of the biopharmaceutical company’s stock valued at $24,800,000 after acquiring an additional 10,213 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $625.60 on Thursday. The company has a market capitalization of $68.39 billion, a P/E ratio of 16.34, a PEG ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $680.43 and a 200 day simple moving average of $786.93. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $605.56 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the business posted $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.